
AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Artificial intelligence is helping researchers identify and design promising drug candidates faster than ever before. Generative models and other AI-enabled approaches are accelerating molecule design and discovery, which is increasing the number of viable candidates in clinical development.





